Research Paper Volume 13, Issue 22 pp 24815—24828

Atorvastatin combined with dexamethasone promote hematoma absorption in an optimized rat model of chronic subdural hematoma

Changes in ZO-1, KLF-2 and NF-κb expression in the capsule of the chronic subdural hematoma model in different treatment groups. (A) Changes in ZO-1, KLF-2 and NF-κb expression in the hematoma capsule in the different treatment groups after modeling. (B) The ZO-1, KLF-2 and NF-κb mRNA expression in the hematoma capsule detected by PCR in the different treatment groups after modeling. * p

Figure 8. Changes in ZO-1, KLF-2 and NF-κb expression in the capsule of the chronic subdural hematoma model in different treatment groups. (A) Changes in ZO-1, KLF-2 and NF-κb expression in the hematoma capsule in the different treatment groups after modeling. (B) The ZO-1, KLF-2 and NF-κb mRNA expression in the hematoma capsule detected by PCR in the different treatment groups after modeling. * p < 0.05 compared with the control group, *** p < 0.001 compared with the hematoma group. # indicates p<0.05, compared with the atorvastatin-only treatment group, ## indicates p<0.01, compared with the atorvastatin-only treatment group; † indicates p<0.05, compared with the dexamethasone-only treatment group; †† indicates p<0.01, compared with the dexamethasone-only treatment group.